Company

Prevail Therapeutics, Inc.

Prevail Therapeutics develops gene therapies for neurodegenerative diseases and rare conditions, based in New York, US.

About

Founded in 2017 and headquartered in New York, US, Prevail Therapeutics, Inc. develops gene therapies for neurodegenerative diseases, including Gaucher disease and GBA1-associated Parkinson's disease. The CEO is Franz Hefti. The company raised USD 125 mn in an IPO in June 2019. Eli Lilly and Company acquired it in December 2020 for USD 880 mn, which could reach USD 1.04 bn upon regulatory approval of its products.

3Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in